Divergent Fortunes For Japan Firms’ Recent U.S. Approvals?
This article was originally published in PharmAsia News
Recent product approvals in the U.S have included major milestones for two Japanese companies and their U.S. alliance partners. But commercial prospects for the two very different drugs are seen varying widely.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.